10-K: LifeVantage Reports Revenue Decline in FY2026

LifeVantage Corporation's annual report for fiscal year 2026 indicates a substantial decrease in net revenue and active accounts, primarily driven by lower sales across key product lines.

Summary

• LifeVantage Corporation reported a net revenue of $182.6 million for the fiscal year ended June 30, 2026, a decrease from $228.5 million in the prior year.
• The company experienced a 21.2% decline in total active accounts, with a 17.6% decrease in active independent consultants and a 24.7% decrease in active customers.
• Operating income decreased to $6.1 million from $12.2 million in the prior year, and net income fell to $5.1 million from $9.8 million.
• The decline in revenue was attributed to decreased sales across most product lines, particularly the MindBody GLP-1 System, TrueScience, and Protandim.
• Cost of sales as a percentage of revenue increased due to higher inventory obsolescence costs and a shift in product mix.
• Selling, general, and administrative expenses increased as a percentage of revenue, primarily due to the overall decrease in sales.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant year-over-year decline in revenue and active accounts, coupled with increased operating expenses as a percentage of revenue.

Positives

• The company successfully launched the P84 System, acquired from LoveBiome, which contributed $9.1 million in revenue.
• The company continues to pay quarterly cash dividends, with a total of $2.3 million paid in fiscal year 2026.
• The company has a new stock repurchase program authorized to repurchase up to $60.0 million of common stock through December 31, 2027.
• The company maintains a strong focus on nutrigenomics and scientific validation of its products.
• The company has a global presence, selling products in multiple countries across the Americas, Asia/Pacific, and Europe.

Negatives

• Net revenue decreased by 20.1% year-over-year.
• Total active accounts decreased by 21.2%.
• Operating income decreased by 50.0% year-over-year.
• Net income decreased by 48.3% year-over-year.
• Cost of sales as a percentage of revenue increased from 19.6% to 22.4%.
• Selling, general, and administrative expenses increased as a percentage of revenue from 30.3% to 32.0%.
• Revenue from the MindBody GLP-1 System decreased significantly to $22.5 million from $40.8 million.

Risks

• Inability to properly motivate and incentivize sales from independent consultants.
• Failure to retain existing customers and independent consultants or attract new ones.
• Independent consultants failing to comply with legal requirements or company policies.
• Dependence on a few key products for a majority of revenue.
• Dependence on third-party manufacturers for product supply.
• Difficulty in obtaining high-quality raw materials or increased costs.
• Risks associated with evolving laws, policies, and contractual obligations related to data privacy and cybersecurity.
• Potential for product recalls and product liability claims.

Future Outlook

The company's future growth is dependent on its ability to effectively expand into new international markets and grow existing markets. The company believes its current cash and cash equivalents and ongoing cash flow from operations will be sufficient to satisfy its cash requirements for at least the next 12 months. However, future funding requirements may necessitate raising additional capital.

Management Comments

• We believe our sales compensation plan engineered for our independent consultants is one of the more financially rewarding plans in the direct selling industry and in line with direct selling industry standards.
• We believe the significant number of customers who regularly and repeatedly purchase our products is a strong indicator of the health benefits of our products.
• We believe that our employees are an essential asset.
• We believe that our cash and cash equivalents balances and our ongoing cash flow from operations will be sufficient to satisfy our cash requirements for at least the next 12 months.

Industry Context

StockSavvy.ai notes that the decline in LifeVantage's revenue and active accounts aligns with broader trends in the direct selling and dietary supplement industries, which can be sensitive to economic conditions, changing consumer preferences, and increased competition.

Comparison to Industry Standards

• The company's sales compensation plan is described as one of the more financially rewarding in the direct selling industry and in line with industry standards.
• The company competes in the dietary supplement and personal care markets, which are described as large, highly competitive, and fragmented, with many competitors having greater financial resources and brand recognition.

Management Changes

Related Party Transactions

• On February 23, 2026, the Company entered into a Securities Purchase Agreement with a stockholder owning more than 10% of the Company's issued and outstanding shares to repurchase 0.1 million shares of common stock for $0.5 million in cash.

Stakeholder Impact

• Shareholders may see continued pressure on stock price due to revenue decline and reduced profitability.
• Independent consultants may face challenges in sales growth due to decreased active accounts and overall market performance.
• Customers may experience changes in product availability or focus due to shifts in product line performance.

Next Steps

• Continue to invest in technology to enhance the LifeVantage experience for independent consultants, customers, and employees.
• Focus on developing and introducing compelling and innovative products.
• Support and re-invest in the business.
• Return stockholder value through quarterly dividends and opportunistic share repurchases.
• Roll out the Evolve Compensation Plan in Thailand in fiscal year 2027.

Key Dates

Recommendation

The significant year-over-year decline in revenue, operating income, and net income, coupled with a decrease in active consultants and customers, indicates a negative business trend. While the company has new product initiatives and a stock repurchase program, the overall performance suggests a cautious approach, making a 'sell' recommendation appropriate until a clear turnaround is demonstrated.

Keywords

nutrigenomics, direct selling, dietary supplements, nrf2, nrf1, collagen, gut health, weight management